Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Workshop of the Carolinas 2024 | Asciminib for the treatment of CML

Gabriela Hobbs • 25 Aug 2024
MPN Workshop of the Carolinas 2024
Chronic Myeloid Leukemia Leukemia Asciminib

In this video, Gaby Hobbs, MD, Massachusetts General Hospital, Boston, MA, briefly discusses the approval of asciminib for the treatment of relapsed/refractory (R/R) chronic myeloid leukemia (CML), a key advancement in the treatment landscape for this hematological malignancy. The agent is also being tested in the frontline setting. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy- Abbvie, BMS, GSK, Novartis, Pfizer, Pharmaessentia, Incyte.

More from Gabriela Hobbs

Cardiovascular risk factors and pulmonary hypertension in patients with MPNs
1:30
Cardiovascular risk factors and pulmonary hypertension in patients with MPNs
Gabriela Hobbs • 25 Aug 2024
Key considerations for physicians when faced with a pregnant patient with MPN
1:06
Key considerations for physicians when faced with a pregnant patient with MPN
Gabriela Hobbs • 25 Aug 2024
Clinical approaches to fertility and pregnancy in patients with MPNs
1:04
Clinical approaches to fertility and pregnancy in patients with MPNs
Gabriela Hobbs • 25 Aug 2024
Future directions in chronic phase CML treatment
1:20
Future directions in chronic phase CML treatment
Gabriela Hobbs • 11 Dec 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals